FDMT4D Molecular Therapeutics, Inc.

$468M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M+32.5% YoY

Gross Profit

-$43M-240.2% margin

Operating Income

-$71M-395.5% margin

Net Income

-$71M-395.4% margin

EPS (Diluted)

$-2.46

Cash Flow

Operating Cash Flow

-$69M

Free Cash Flow

-$78M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$353M

Total Liabilities

$34M

Stockholders' Equity

$319M

Cash & Equivalents

$153M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$14M	+32.5%
Gross Profit	-$43M	-$39M	-9.9%
Operating Income	-$71M	-$57M	-25.9%
Net Income	-$71M	-$57M	-25.8%

FDMT FY 2021 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena